Aerosol barriers in pediatric anesthesiology: Clinical data supports FDA caution.

Abstract

BackgroundThe onset of the COVID19 pandemic drove the rapid development and adoption of physical barriers intended to protect providers from aerosols generated during airway management. We report our initial experience with aerosol barrier devices in pediatric patients and raise concerns that they may increase risk to patients.MethodsIn March 2020, we developed and implemented simulation training and use of plastic aerosol barrier devices as a component of our perioperative COVID‐19 workflow. As part of our quality improvement process, we obtained detailed feedback via a web‐based survey after cases were performed while using these aerosol barriers.ResultsBetween March and June 2020, 36 pediatric patients age 1mo‐18years with anatomically normal airways and either PCR confirmed or suspected COVID‐19 were intubated under an aerosol barrier as part of urgent or emergent anesthetic care at our institution. Experienced providers had more difficulty than expected in six (16.7%) of the cases with four cases requiring multiple attempts to secure the airway and two cases involving pronounced difficulty in a single attempt. The aerosol barrier was perceived as a contributing factor to difficulty in all cases.ConclusionThe use of barriers may result in unanticipated difficulties with airway management, particularly in pediatric patients, which could lead to hypoxemia or other patient harm. Our initial experience in pediatric patients is the first such report in patients and provides clinical data which corroborates the simulation data prompting the FDA to withdraw support of barriers.